$ASND News

Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase (Initiating Buy)

Citigroup Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $355

ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate

Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $329

Ascendis Pharma (NASDAQ:ASND) Is Posting Healthy Earnings, But It Is Not All Good News

Barclays Maintains Overweight on Ascendis Pharma, Raises Price Target to $345

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Ascendis (ASND) Q1 2026 Earnings Call Transcript

Wells Fargo Maintains Overweight on Ascendis Pharma, Lowers Price Target to $326

Ascendis Pharma A/S Q1 Earnings Call Highlights

Ascendis Pharma Reports First Quarter 2026 Financial Results

Ascendis Pharma Q1 Adj. EPS $0.32 Beats $0.21 Estimate, Sales $288.770M Miss $318.050M Estimate

New 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 Years

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

Ascendis Pharma A/S (ASND): Billionaire Joe Edelman Is Bullish on This Stock

European Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

We Might See A Profit From Ascendis Pharma A/S (NASDAQ:ASND) Soon

Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq

Ascendis Pharma Commences Trading Of Its Ordinary Shares On Nasdaq, Replacing Listing Of ADSs